secwatch.observer — SEC 8-K summary
======================================

Issuer:     ATOSSA THERAPEUTICS, INC. (ATOS)
CIK:        0001488039
Form:       8-K
Filed at:   2026-03-25T23:59:59+00:00
Accession:  0001193125-26-124393
Event type: earnings
Sentiment:  positive
Materiality: 0.70
Item codes: 2.02, 9.01
LLM model:  deepseek-v4-flash:cloud

Atossa Therapeutics Reports Q4 and FY2025 Results, Highlights (Z)-Endoxifen Progress in DMD
--------------------------------------------------------------------------------

- Atossa reported FY2025 operating expenses of $37.1M, up from $27.6M; R&D expenses increased 50% to $21.2M.
- Received FDA Rare Pediatric Disease and Orphan Drug designations for (Z)-endoxifen in Duchenne Muscular Dystrophy.
- Added Kathy Puyana Theall, M.D. and Adebola Giwa, M.D. as Medical Directors for breast oncology and rare diseases.
- Interest income decreased to $2.4M from $4.1M; no impairment charge in 2025 vs $1.7M in 2024.
- (Z)-endoxifen being evaluated in multiple settings including breast cancer and rare diseases DMD and MAS.

Source:
  EDGAR index:    https://www.sec.gov/Archives/edgar/data/1488039/000119312526124393/0001193125-26-124393-index.htm
  Primary doc:    https://www.sec.gov/Archives/edgar/data/1488039/000119312526124393/atos-20260324.htm
  HTML page:      https://secwatch.observer/filing/0001193125-26-124393

License: Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer